+ T Regs in vivo using adjuvants or pharmacological agents such as low dose steroids or vitamin D3 could represent novel approaches to induce antigen-specific tolerance in human diseases including allergic asthma, autoimmune disease and the rejection of transplanted organs.
INTRODUCTION
Allergic diseases are immunological disorders that have increased in prevalence over the past three decades and affect ~15% of people in industrial countries [1] . Consequently, the current healthcare expenditures for conditions such as allergic rhinitis and asthma are enormous in the western countries. Allergic rhinitis and asthma are manifestation of inflammatory immune responses in the respiratory mucosa to environmental antigens in genetically susceptible individuals. These complex genetic disorders are also influenced by environmental factors and characterized by an inflammatory cellular influx composed of T lymphocytes, basophils and eosinophils resulting in exaggerated T-helper 2 (Th2) responses [2, 3] . The activation of CD4 + T cells plays a major role in the development of allergic disorders. Thelper subsets include T helper 1 (Th1), Th2, Th3, Th17 and T Regs and their transcriptional regulation elements [4] [5] [6] are shown in Fig. (1) . Th1 cells characteristically interact with foreign antigens/pathogens (bacteria, viruses) and secrete interleukin 2 (IL-2), tumour necrosis factor-alpha (TNF-), interferon-gamma (IFN-) and under certain circumstances IL-10. Th2 cells on the other hand, are the hallmark of allergic diseases and have been shown to be involved in the induction of humoral immunity and in particular in immunoglobulin switching in B-cells in favour of IgE with IL-4 and/or IL-13 as determining switch factors. Other Th2 cytokines involved during allergic reaction include IL-5 (facilitates eosinophilic inflammation and induces nasal symptoms and airway inflammation), IL-9 (engages in mast cell maturation, and mucus hyper-secretion and airway hyperreactiv-*Address correspondence to this author at the Department of Allergy & Clinical Immunology, National Heart & Lung Institute at Imperial College London, Exhibition Road, London SW7 2AZ, UK; Tel: (+44) 207 594 3182; E-mail: k.nouri-aria@imperial.ac.uk ity), and IL-10 (with both inflammatory and antiinflammatory activities) [7] . The over production of Th2 cytokines (IL-4, IL-5, IL-9 & IL-13) is deemed to play a prominent role in the target organ, resulting in the upregulation of adhesion molecules like vascular cell adhesion molecule-1 (VCAM-1) on the endothelial cells facilitating the infiltration of mast cells, eosinophils, T cells and basophils into the respiratory mucosa [8, 9] . Chemokines such as RANTES, eotaxin, monocyte chemoattractant protein-4 (MCP-4), thymus and activation regulated chemokine (TARC) and macrophage derived chemokine (MDC) released from epithelial cells all serve as chemoattractants for eosinophils, basophils and T lymphocytes [10, 11] . In addition eosinophils are major players in the late phase responses release an array of proinflammatory mediators including cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, and major basic protein, and serve as a major cell source of IL-3, IL-4, IL-5, GM-CSF, and IL-13 [12] .
T helper 17 (Th17) cells, a recently identified T helper subset, preferentially produce interleukin-17A (IL-17A), IL-17F, IL-21, and IL-22. Th17 cells and their cytokines mediate host defense mechanisms to various infections, and are regarded as effector candidates involved in the immunopathogenesis of many autoimmune diseases [13, 14] .
The role of Th2-driven immune responses has been decisively established in the development of allergic diseases. Nevertheless environmental factors and the genetic predisposition of allergic individuals are also believed to contribute, as co-factors, in the severity of these Th2 diseases. Conversely, the lack of response to allergens in nonatopic healthy individuals and the mechanisms by which such immune tolerance is induced and regulated are poorly understood. This article summarises in vitro & in vivo evidence for the functional abilities of regulatory T cells (T Regs ) in controlling cell proliferation and cytokine production in health and in a number of immunological related disorders including allergic diseases and discusses the possibility of manipulating T Reg for treatment of allergic conditions such as allergic rhinitis.
REGULATORY T CELLS (T REGS )
The interest in regulatory T cells (T Regs ), formerly known as suppressor cells, was revived in the 1990s following the report that athymic nude (nu/nu) mice when injected with CD4 + T cells depleted of CD25 + subset, developed multiorgan autoimmune diseases [15, 16] and that these autoimmune phenomena could be reversed by the adaptive transfer of CD4 + CD25 + T cells from naïve mice to the athymic mice. This landmark observation provided compelling evidence for the putative regulatory role of CD4 + CD25 + T cells in the control of immune responses and generated considerable interest in all aspects of basic and clinical immunology. Further observations confirmed the existence of CD4 + CD25 + T Regs in the peripheral blood and lymphoid tissues in man [17] [18] [19] [20] . Numerous studies on CD4 + CD25 + T cells revealed a critical role for T Regs as the controller of immune responses in a number of clinical settings such as autoimmunity, tumour and microbial infection, transplantation, and allergy. Thus the level of T Reg mediated suppression is a critical factor in determining the development of immunity or progression to disease. For example the lack of adequate suppression in immune responses to self antigens or allografts result in autoimmunity or graft rejection which contrasts to over suppression of immune responses to tumour antigens in cancer.
CD4
+ CD25 + T Reg cells constitutively express the highaffinity interleukin-2 (IL-2) receptor -chain (CD25), a receptor which is critical for IL-2 signalling and events leading to maintenance, homeostasis and the function of T Reg 
MARKERS OF T REGS
Naturally occurring CD4 + T Regs express various cell surface molecules commonly associated with activated and/or memory T cells. These include CD25, CD45RB low CD62L, cytotoxic T-lymphocyte antigen-4 (CTLA-4, or CD152) and glucocorticoid-induced tumor necrosis factor receptor (GITR), OX40 and programmed death-1 (PD-1) antigen [44] [45] [46] . The expression of chemokine receptors CCR4 & CCR6 has also been reported in T Regs [47] . The lymphoid homing receptors CD103 and CD62L and molecules such as perforin and granzyme A are also in the list of markers expressed by T Regs [48] . Although none of these surface markers are uniquely expressed by natural T Regs , the high level of expression and their constitutive nature have made them useful surrogate makers for the functional T Regs . The search for molecules, which exclusively identify cell surface markers that define T Regs , has led to the identification of an additional marker with potential specificity for T Regs . 
CLTA-4
In contrast to CD28 (a costimulatory molecule constitutively expressed on T cells), CTLA-4 is transiently expressed on activated T cells, initially within the cytoplasm, followed by expression on the cell surface membrane. Ligation of CD28 with its counter parts (B7 family molecules) is critical for the induction of immune responses of naïve CD4 + cells, whereas CTLA-4 ligation plays a crucial role in downregulating T cell responses by inhibiting IL-2 production and other components involved in the machinery cell cycle progression. In experimental models, the blockade of CTLA- 
GITR
GITR, a member of the tumour necrosis factor (TNF) receptor family, is expressed on CD4 T cells after TCR ligation and plays a major role in the regulation of TCR-driven cell activation and cell death [56, 57] . GITR is constitutively expressed on T Regs in mice, but only ~10% of human T Regs are GITR positive [58] . The ligation of GITR with its ligand on APC results in inhibition of immune reactions through tolllike receptors (TLRs). Agonistic anti-GITR seems to function by intervening with the immunosuppressive effects of T Regs on the effector T cells, but the exact molecular mechanisms have not yet been elucidated.
OX-40
OX-40 (CD134), another member of the TNF family, is also constitutively expressed by T Regs . Similarly to GITR, OX40L ligand (CD134L) is expressed by APCs (B cell, DC, and macrophages), and activated endothelial cells [59] . Triggering of OX40 on T Regs by administration of OX40L has been shown to block the inhibitory activity of T Regs in mice [60] as well as inhibiting the induction of IL-10-producing Tr-1 cells from naïve CD4 T cells in man [61] . OX40L has the ability to enhance immunity and break immunological tolerance in certain types of tumours.
SUBTYPES OF T REGS
Naturally occurring T Regs : T Regs represent a highly heterogeneous populations of CD4 + T cells (Fig. 2) . Naturally occurring CD4 + CD25 high T Reg cells are a distinct lineage of T Regs that originate in the thymus and are probably committed to debilitate immune responses against self-antigens [62, 63] . Naturally occurring T Regs , account for 5-10% of peripheral CD4 + T cells and have the ability to inhibit the activation and proliferation of effector T cells [64] . The foremost phenotypic markers of T Regs are the surface expression CD4 and CD25 and the nuclear expression of the transcription factor Foxp3, tools that natural T Regs are equipped with before leaving the thymus [65] . Foxp3 + CD4 + T Regs can also be generated de novo from naive T cells in a TGF--dependent environment by TCR triggering. It has been reported that naturally occurring, but not in vitro TGF--induced T Regs display stable Foxp3 that is associated with selective demethylation of an evolutionarily conserved element within the Foxp3 locus named TSDR (T Reg -specific demethylated region). Naturally occurring regulatory T cells that coexpress high levels of CD25 and Foxp3 exert strong suppressor activity following TCR stimulation and have been reported both in mice and humans [66, 67] . While these cells are thought to originate predominantly from the thymus [68, 69] , a number of in vitro studies have demonstrated that cells with similar characteristics can be generated from peripheral T cells under appropriate conditions that use TCR signalling pathways [70, 71] . Naturally occurring T Regs are, in particular, involved in the maintenance of normal homeostasis, prevention of autoimmunity and graft rejection and over expression of Foxp3 by CD4 + CD25
+ T Regs has been demonstrated to play a critical part in tumour growth. Experimental models of inflammatory bowel disease [72] and clinical conditions such as atopic dermatitis [73] , asthma [74] and a number of autoimmune conditions [75, 76] The presence of T Regs in inflamed tissues such as pancreatic islets, synovia of arthritic joints, colitis lesions, asthmatic lung, skin, intestinal tissue of graft-versus-host disease (GVHD), cardiac and renal allografts, various tumours, virus and parasite-infected tissues, are all suggestive of the potential role of T Regs at the site of inflammation [77] . Some studies have demonstrated that the tissue-resident T Regs have functional ability to regulate local immune responses. For example, in the skin allograft setting, the T Reg -infiltrated allograft was capable of transferring antigen-specific tolerance when the tissue was re-transplanted to a new host, suggesting that the tolerant skin graft harbored functional T Regs [78] . In one study, depletion of T Regs within the tumour was sufficient to promote a productive anti-tumour response and induce tumour regression [79] . More recently, Foxp3 mRNA levels in urine samples inversely correlated with serum creatinine levels in patients with acute renal graft rejection. In fact, higher levels of Foxp3 mRNA in urine predicted reversal of acute rejection, while lower levels of Foxp3 mRNA level identified as a marker of graft failure [80] . Collectively, these results suggest that T Regs can function within the peripheral tissue to suppress inflammation and to prevent tissue damage. [85, 86] .
TYPE 1 REGULATORY T CELLS (TR-1)
Tr-1 cells are defined by their ability to produce high levels of IL-10 upon repetitive exposure with antigens. IL-10 production by Tr-1 cells may be associated with or without the production of TGF- [87] . A subset of Tr-1 cells can also be generated in vitro by stimulation naive CD4 + T cells in the presence of IL-10, IFN-, or a combination of IL-4 and IL-10 [87, 88] . Addition of Dexamethasone (Dex) and vitamin D 3 have been shown to induce the differentiation of naive CD4 + T cells to IL-10 secreting Tr-1 cells both in man and mice [89, 90] .
Antigen specific CD4 + T cell clones when stimulated in vitro in the presence of IL-10, mature to a distinct cytokine profile that is different from those of Th1 or Th2 cells [91] . These CD4 + clones develop large capacity to release high levels of cytokines such as IL-10 and also TGF-. This inducible cell type of T Reg has been named Tr-1 cells. The adaptive transfer studies using the IL-10 producing T cells in SCID mice inhibited the development of colitis when these cells were co-administered with CD4 + CD45RB hi splenic T cells [91] . Stimulation of CD4 + T cells derived from cord blood with allogeneic immature DCs gave rise to IL-10 producing Tr-1 cells [92] . In another study, in vivo generation of Tr-1 cells was achieved by administration of IL-10 and rapamycin in diabetic mice after pancreatic islet transplantation. However, when the IL-10 activity was blocked using anti-IL-10R, mice rapidly induced graft rejection. Thus the combination of rapamycin plus IL-10 not only prevented allograft rejection but also induced Tr-1 cells that mediated stable antigen-specific, long-term tolerance in vivo [93] .
The inducible CD4 + T Regs (iT Regs ) comprise not only IL-10 producing Tr-1 cells, but also another distinct population of T Regs, so called TGF-1 secreting T-helper cell type-3, "Th3 cells" which can be antigen-specific or antigen non-selfspecific, and can develop after antigen encounter in the periphery. The expression of Foxp3 by Tr-1 and Th3 remain controversial.
TH3 CELLS
Administration of antigens via oral route has long been recognized to induce immune tolerance in several animal models of autoimmune diseases including experimental autoimmune encephalitis, uveitis, thyroiditis, myasthenia, arthritis, colitis, and diabetes in NOD mouse. In these experimental models TGF--producing Th3 cells are considered to be responsible for provoking oral tolerance and are assumed as the main regulator of antigen immune responses [94] . Nonetheless, the role of Th3 in the development and involvement of T Regs is unclear, despite its influence in the induction of oral tolerance through a mechanism which possibly entails TGF- [95, 96] . An increasing body of evidence however suggests that Th3 cells may overlap with naturally occurring CD4 + CD25 + T Regs because of the established influence of TGF-in the induction and development of T Regs . Further evidence for this argument is provided by the observation that oral administration of autoantigen in mice suffering from autoimmune conditions resulted in attenuation of the disease, the mechanism of which is believed to be through Th3 + cells [96] .
MECHANISMS OF SUPPRESSION
Cytokines: The suppressive cytokines TGF-and IL-10 have been implicated as active players in the effector function of T Regs [85, 97, In vivo evidence against cell-cell contact-dependent suppression by T Regs was provided by the administration of suppressive cytokines, IL-10 and TGF-, controlling autoimmune responses and prevention of graft versus host reactions in experimental models of autoimmunity and transplantation. Blocking of IL-10 receptor with appropriate antibodies, but not the adaptive transfer of CD4 + CD25 + T Regs , into mice grafted with allogeneic skin graft markedly accelerated transplant rejection [106] . The monitoring role of IL-10 in CD4 + CD25 + T Reg -mediated control of murine model of transplantation tolerance [107] , chronic parasite infection [108] , and type 1 model of diabetes [109] have also been reported. IL-10 was shown to be indispensible for the regulation of mouse model of colitis as IL-10-deficient mice developed spontaneous colitis mediated by Th1 CD4 + T cells [110] . In one study IL-10-producing CD4 + CD25 + Foxp3 + T Regs were found to be selectively present within the colonic lamina propria of both colitis mice and wild-type mice [75, 111] . The inflamed intestine of patients with inflammatory bowel disease also showed accumulation of CD4 + CD25 + Foxp3 + T Regs , suggesting impaired function, but not physical absence of T Regs in the development of the disease. Suppression of T Regs via IL-10 has also been reported in a number of in vivo experimental models of T Regs to control inflammation and homeostatic expansion of effector cells [112, 113] .
Discrepancies between mechanisms used in suppression in vitro and in vivo might be explained by differences in the stage of T-cell activation in each setting. Powrie and colleagues [114] highlighted that while IL-10 was a key player in T Reg inhibition of colitis-mediated by antigen-activated T cells, it was not essential for the regulation of colitis induced by naive T cells, i.e. IL-10 was relevant in the T Regs control of effector function within inflamed tissue but not for T-cell activation and/or differentiation events in lymph nodes.
The occurrence of Foxp3 + T Regs in the intestinal lamina propria or its presence in the central nervous system could be accountable for regulation of colitis and experimental allergic encephalomyelitis (EAE), through IL-10 locally secreted by T Regs [115, 116] . Interestingly splenic or tonsillar T Regs do not appear to synthesize or secrete IL-10 in situ [117] , endorsing that "naturally occurring" T Regs in primary lymphoid organs do not express IL-10 de novo in the absence of stimulation.
Considerable evidence supports a fundamental role for IL-2 in the maintenance and survival of natural T Regs since most Foxp3 + T Regs express CD25 molecule, the high affinity IL-2 receptor. In agreement with these findings was a substantial reduction in Foxp3 + T cells in IL-2-deficient mice [118] . Furthermore, neutralization of circulating IL-2 by anti-IL-2 antibody treatment specifically diminished the number of CD25 + CD4 + T cells resulting in the induction of organ-specific autoimmune diseases [119] . These observations may reinforce the requirement of IL-2 for the survival of natural T Regs , although the main cell source of IL-2 seems to be T cells other than T Reg populations themselves [120] . IL-2 has also been shown to augment the expression of The newly discovered inhibitory cytokine, IL-35, also appears to contribute to T Reg suppression [122] . EBVinduced gene 3 was identified to be overrepresented in mouse CD4
+ CD25 + T cells in a genomic screen. EBV-3 gene encoded the IL-27 -chain which pairs with IL-27-to form IL-27 or with IL-12-to form the new cytokine IL-35. Unlike IL-10 and TGF-, IL-35 seems to be involved in suppressive function both in vitro and in vivo. Moreover, the ectopic expression of IL-35 in T cells confers the regulatory property of IL-35 for T Regs [122] . Although IL-35 and IL-12 are expressed by several cells other than T Regs within the immune system, IL-35 may nevertheless represent an important therapeutic target for the modulation of immunity.
The modulation of cyclic adenosine monophosphate (cAMP) levels in the target cells by T Regs has also been reported as a further mechanism that initiates an inhibitory pathway proceeding to restrain cellular proliferation and differentiation in effector cells. This will result in the reduction in IL-2 and IFN-gene expression through protein kinase A (PKA) which consequently blocks the nuclear factor-B (NF-B) activity [123] .
Cell-cell contact:
The use of transwell membrane experiments which allows the exchange of soluble factors between the wells but prevents a direct physical contact between CD4 + CD25 + T Regs and CD4 + CD25 -effector T cells provided convincing evidence for cell-cell contact dependent suppression by T Regs in vitro [124] .
The suppression of cell proliferation in vitro involves contribution from several T cell accessory molecules such as CTLA-4 (CD152), Lymphocyte-activation gene (LAG)-3 and possibly other molecules such as GITR, OX40L expressed on T Regs in a contact-dependent fashion [125, 126] . Upon stimulation, CTLA-4 expression is upregulated on CD4 + CD25 + cells more than on CD4 + CD25 -T cells, supporting a possible role for CTLA-4 in suppression induced by T Regs . In concurrence with this hypothesis was the administration of anti-CTLA-4 mAb into normal mice over a period of time that elicited autoimmune gastritis and a murine model of colitis, two clinical conditions similar to those observed in mice following the depletion of CD4 + CD25 + T cells [127, 128] . In addition, ectopic expression of Foxp3 in naïve T cells enhanced the expression of CTLA-4 and increased suppressive ability of T Regs , entailing the involvement of both Foxp3 and CTLA-4 molecules in the inhibitory function of CD4 + CD25 + T cells [129] . One possible mechanism of suppression induced by CTLA-4 is the competition between CTLA-4 and CD28 with co-stimulatory molecule for B7-1/B7-2 present on APCs instigating cell signalling. An alternative suppressive mechanism(s) engaged by CTLA-4 has been proposed to include the induction of indoleamine 2,3 dioxygenease (IDO) in dendritic cells possibly through activation of B7-1 & B7-2 antigens expressed on these cells and consequently triggering T Reg activation [130] . IDO is responsible for the metabolism of an essential amino acid, tryptophan, required for the activation of CD4 These observations collectively support the proposition that different mechanisms of suppression are employed by T Regs in in vitro versus in vivo conditions. While a contactdependent mechanism dominates during in vitro suppression, soluble factors such as IL-10, TGF-and possibly IL-35 seem to be imperative in the induction of suppression in vivo.
T REGS IN ALLERGIC DISEASES
Impairment in the function of regulatory T cells has been postulated to be responsible in the evolution of autoimmune diseases, rejection of solid organ transplants, and uncontrolled tumour growth. In the last three decades allergic diseases such as asthma, atopic dermatitis and rhinitis have been rising in prevalence worldwide. The well-recognized role of natural T Regs in preventing autoimmune diseases suggests CD4 + CD25 + T Regs may also play a critical role in hampering allergic diseases and implies a low frequency and/or a weakened function of allergen specific T Regs may be accountable for the increase in the number of cases with allergy seen in the past 30 years. Thus, better understanding of mechanisms of T-cell regulation of Th2 responses seen in allergic diseases may help in developing more effective therapeutic strategies for treatment of allergic conditions. The regulatory influence of Tr-1 cells in controlling Th2 type responses was established by the adaptive transfer of IL-10 producing CD4 + CD25 + cells from unchallenged mice to OVA sensitized mice resulting in the resolution of inflammatory responses in the bronchial mucosa [135] . In man, the influence of CD4 + CD25 + T Regs in regulating immune reactions to allergens has been identified [136] by the observation that the proliferative responses to allergens was completely absent in healthy volunteers in contrast to those of atopic subjects where T cell responses to allergens were shifted towards Th2 producing cytokines (IL-4, IL-5 & IL-13) [137] . These observations insinuate an active immune surveillance by T Reg populations operates in the healthy nonatopic individuals. The majority of allergen-specific T cells in these healthy individuals were of IL-10-secreting Tr-1 type. This report also supports the concept that rather than an imbalance between Th1:Th2 responses, the regulation of Th2 cell function may be hampered in atopy. It would also provide a plausible explanation as to why no immunological responses seen in non-atopic healthy volunteers following exposure to allergens.
In concordance with these findings was the lack of proliferative T cell responses to cows' milk antigen in healthy children. Depletion of CD4 + CD25 + T cells from PBMCs however reversed T cell responses to cow's milk antigen, implying that the food tolerance to dietary antigens is also imposed by CD4 + CD25 + T Regs [138] . Contrary to these data, children who had outgrown cows' milk allergy showed increased frequencies of circulating CD4 + CD25 + T cells and decreased in vitro proliferative response to bovine -lactoglobulin (a milk protein) when compared with children who remained clinically milk sensitive [139] . A similar state of IL-10-associated T cell induced anergy has been reported in hyperimmune individuals i.e. bee keepers, who had received multiple bee stings. The intracytoplasmic IL-10 + cells from these individuals were co-localized to activated CD4 + CD25 + T cells with specificity for bee venom antigens [140] .
A reduction in absolute numbers and proportions of the Foxp3 + CD4 + CD25 + have been described in the blood and in the nasal mucosa of allergic rhinitics. In several in vitro studies, CD4 + CD25 + T cells from aeroallergen sensitive individuals (e.g. grass & birch pollens, cat and HDM) were found to be defective resulting in high proliferative responses and IL-5 secretion when CD4 + CD25 + T cells were co-cultured with autologus allergen-stimulated CD4 + CD25 T cells [140 -142] . The dysregulation of CD4 + CD25 + T Regs in the atopics controlling IL-13 and IL-5 production [143] was most pronounced during the peak of birch and grass pollen season. In contrast, CD4 + CD25 + T cells from both allergic and non-allergic individuals were potently suppressive of T-cell proliferation and Th2 cytokine production to allergens outside of the pollen season.
The antigen specificity of T Reg and its role in the induction of tolerance remains controversial. However, the observations that the adoptively transferred polyclonal T Reg cells from healthy donors into myasthenic rats inhibited the progression of experimental autoimmune MG and led to downregulation of humoral acetylcholine receptor-specific responses, endorsing antigen specific T Regs may exist systemically and locally in these rats. Although the number of CD4 + CD25 + cells in the spleen of treated rats remained unchanged, the proportion of CD4 + CD25 + cells expressing Foxp3 was significantly elevated [144] . In another study T Regs from non-allergic healthy subjects suppressed proliferation of influenza antigen as well as birch pollen stimulated effector cells, whereas CD4 + CD25
+ cells from allergic patients were only capable of dampening proliferative responses of T cells to influenza antigen, but not birch pollen stimulated cells. Similarly, the regulation of Th2, but not Th1 cytokine production by CD4 + CD25 + cells was impaired in allergic patients, upon stimulation with birch pollen extract. Neutralization of IL-10 led to increased production of IFN-and TNF-in the atopics and non-atopic controls, substantiating a dysregulation of allergen-specific CD4 + CD25 + T cells in atopic subjects. The increased in TNFproduction following neutralization of IL-10, however suggests counter-acting properties of IL-10 and TNF-, and that IL-10 producing T Regs are possibly involved in promoting tolerance. In contrast, the elevated levels of TNF-may be involved in the ongoing process of inflammatory responses [145] .
Further evidence for the co-existence of allergen (Der-p 1)-specific and streptokinase (SK) specific-CD4 + CD25 + Foxp3 + T Regs in the peripheral blood of atopic individuals was reported by Maggi L. et al. [146] . have a large repertoire for self-specific T-cell receptors and suppress immune responses via contact-dependent mechanisms, the inducible T Regs consist of self-and non-self-specific cells that recognise autoantigens as well as foreign antigens, and are capable of suppressing a wide range of immune cells via high concentrations of TGF 1 (possibly Th3 cells) or IL-10 10/TGF 1 producing Tr-1 cells [146, 147] . Although antigen exposure is required by T Regs to initiate suppressive activity, in vitro studies revealed that once they are activated, T Regs inhibit immune responses in an antigen-nonspecific manner [147] .
The role of TGF-in the control of atopic diseases has been recently unveiled. TGF--deficient mice have been demonstrated to show a higher susceptibility to asthma-like lung inflammation than their healthy counterparts [148] . A mouse model of food allergy showed a significant reduction of secreted IgA antibodies, a class of immunoglobulin which is closely regulated by TGF-, in the gut. Interestingly, recovery from food allergy in these mice was correlated with local production of TGF- [149] .
The expression of Foxp3 and GITR in normal skin and in a panel of different inflammatory dermatoses revealed that most Foxp3 + T cells co-expressed with the suppressive molecule, GITR. In atopic dermatitis and psoriatic skin, a dysregulation of effector T cells has also been reported by the absence of CD4 + CD25 + FoxP3 + T cells of in the lesional region and in the atopy patch test areas of the skin, despite the abundant expression of IL-10 and TGF-as well as receptors for these cytokines in the dermis [150] . In normal skin Foxp3 + T cells were abundant, their frequency was, however, significantly lower than in patients with spongiotic dermatitis, psoriasis, and lichen planus, implying a role for the transcription factor Foxp3 in regulation and control of these skin conditions.
MODULATION OF T REGS WITH TREATMENT
Corticosteroid: The administration of glucocorticoids, inhaled or systemic, in patients with severe asthma showed increases in the transcription factor Foxp3 and IL-10 mRNA expression in the bronchial mucosa. The expression of + T cells in murine lymphoid tissues. Thus, the combination of glucocorticoids with or without IL-2 may provide a novel approach for the treatment of autoimmunity as well as allergic diseases [154] .
hi T cells expressing Foxp3 in peripheral blood and bronchoalveolar lavage fluid of asthmatic children compared with children with cough or healthy children showed a reduction in the numbers of regulatory T cells in asthmatic children [155] . In asthmatic children, inhaled corticosteroid treatment was associated with an increased proportion of CD4 + CD25
hi T cells in both peripheral blood and BALF and an improvement in suppression of proliferation and cytokine/chemokine production by CD4 + CD25 -responder T cells. The lower level of IL-10 in the bronchoalveolar lavage fluid of adult asthmatic patients compared with healthy controls has previously been reported [156] . Neutralization studies using anti-IL-10 almost abolished the suppressive effect of Tr-1 cells in vitro and further strengthened the role of this immunesuppressive cytokine in the control of Th2 responses and in the maintenance of T cell homeostasis [157] .
Strategies that convert transient glucocorticoid-induced T Reg activity into a stable phenotype should probably be considered to improve the treatment strategy in allergy and asthma.
Specific allergen immunotherapy (SIT)
is highly effective in selected patients with IgE-mediated disease who are monoallergic [158, 159] . SIT was first described almost 100 years ago [160] and involves subcutaneous administration of small but increasing doses of allergen using a relatively crude extract.
Allergen immunotherapy is the only treatment to date that can affect the natural course of allergic rhinitis, conjunctivitis, allergic reactions to stinging insects and allergic asthma [161, 162] . Conventional allergen-desensitization immunotherapy prevents further allergen sensitisations and the development of asthma in patients with allergic rhinitis [163] . The clinical improvement following allergen immunotherapy is sustained for years after cessation of treatment, thus SIT is believed to modify the underlying immunological mechanisms of allergic responses [164, 165] . The specific mechanisms by which allergen immunotherapy reduces allergic symptoms have been studied for decades. Induction of blocking antibody i.e. IgG4, a shift from Th2 to IFNproducing Th1 cytokine profile [166] + CD25 + regulatory T cells have emerged as potential mediators of immune tolerance not only in numerous murine models of immunopathology, but also following grass pollen immunotherapy in man [167] .
In house dust mite-sensitive mice, peptide IT increased the number of CD4 + CD25 + T Regs in the peripheral blood and the adaptive transfer of CD4 + CD25 + T Regs prevented the induction of experimental allergic encephalomyelitis [169] . A marked increase was found in the number of FoxP3 + CD4
+ CD25 + T Regs in the peripheral blood of patients with rheumatoid arthritis who were successfully treated with peptide IT, dnaJP1 derived from the bacterial heat shock protein) [170] . Although these CD4 + CD25
+ T Regs had suppressive capacities in vitro, their effects in vivo depended on the induction of antigen-specific IL-10 producing Tr-1 cells [171] . As shown above, Tr-1 cells are likely to play a crucial role in the control of allergic disease. The major effector molecules of Tr-1 cells in this setting are the suppressive cytokines IL-10 and TGF-.
The suppressive mechanisms of Tr-1 cells not only involve cytokines IL-10 and TGF-, but also involve molecules such as CTLA-4 and PD-1 antigens. IL-10 inhibits CD28 tyrosine phosphorylation and prevents the binding of phosphatidylinositol 3-kinase p85, hence reducing the co-stimulatory CD28 signalling pathway [172] . Induction of antigen-specific Tr-1 cells can thus re-direct inappropriate immune responses against allergens using a broad range of suppressor mechanisms. Wasp venom-or phospholipase A2-pulsed dendritic cell stimulation of CD4 + CD25 -T cells from healthy donors resulted in inhibition of proliferation and Th2 cytokine production by T Regs at 10-fold lower than the optimal concentration. Whereas IFN-production was inhibited at all concentrations, suggesting that the threshold of response is different between allergic and non-allergic individuals [173] .
The autocrine action of IL-10 and TGF-includes initiation and the induction of peripheral T cell tolerance and plays a crucial role in the mechanisms of allergen-SIT [174, 175] . Reactivation of T cells tolerized by IL-10 and TGFcan result in the distinct pattern of either Th1 or Th2 cytokine profiles depending on the cytokine milieu in the target organ [176] . Antigen presentation to the anergic T cells was, however, fully restored in the presence of IL-2 or IL-15 as documented by the secretion of IFN-, but not IL-4 [177] . IL-10 and TGF-expressing cells were increased significantly in the nasal mucosa of GP-IT patients, suggesting the immunological changes are not only systemic, but also occur in the target organ, i.e. nasal mucosa.
Another crucial change seen after successful allergen-SIT is a shift in the balance from IgE to IgG, in particular of the IgG4 subclass which is under the control of IL-10. Although peripheral tolerance has been demonstrated specifically in T cells, the capacity of B cells to produce specific IgE and IgG4 antibodies is not eliminated during allergen-SIT. GP-IT resulted in blunting of seasonal increases in serum allergen Phl p 5-specific IgE, increases in Phl p 5-specific IgG, and in particular Phl p 5-specific IgG4, the latter requires IL-10 for class switching [174] . Phl p 5-specific IgA rose modestly and it was predominantly of mucosal IgA2 subclass and correlated with the local expression of TGF- [175] . These two independent studies have shown that IL-10-and TGF-producing T cells in humans are generated in vivo during the course of allergen-SIT, implicating that high and increasing doses of allergens administrated during the course of GP-IT induce the proliferation and activation of Tr-1 cells [142] . Jutel et al. reported the suppression induced by CD4 + CD25 + Tr-1 + cells was partially blocked by neutralization of antibodies against secreted forms or membrane-bound IL-10 and TGF- [157] . Thus, in addition to their cellular inhibitory influence, IL-10 and TGF-secreted by Tr-1 cells can skew the antibody production from immunoglobulin E (IgE) towards the non-inflammatory isotypes IgG4 and IgA respectively.
In a recent article, striking numbers of Foxp3 expressing CD25 + and CD4 + cells were identified in allergic rhinitics who completed a successful course of GP-IT. Seasonal elevations in dual-positive Foxp3 + CD4 + and Foxp3 + CD25 + cells in these patients were accompanied by suppression of local allergic inflammation, indicative of a regulatory phenotype post immunotherapy (Fig. 3) . Foxp3-positive and Foxp3-negative IL-10 + CD25 + T cells co-existed in the nasal mucosa supporting the emergence of phenotypically distinct populations of regulatory cells i.e. Foxp3 expressing adaptive T Regs and IL-10 producing Tr-1 cells after GP-IT [168, 174] . These findings are in agreement with those reported in murine models of colitis and in patients with ulcerative colitis and/or Crohn's disease, in whom IL-10 producing Foxp3 + CD4
+ CD25 + cells were present at increased density in the colon and the presence of IL-10 was associated with amelioration of colitis [168, 178] . These findings support strategies targeting increases in local T Regs numerically and/or functionally might be beneficial in the treatment of allergic rhinitis. Similar observations using venom-specific IT inducing a significant progressive increase in the frequency of regulatory T cells as defined by CD25 bright and/or Foxp3 + CD4 + T cells was reported by Pereira-Santos. The increased number of circulating regulatory T cells correlated with the venom-specific IgG4/IgE ratio shift, confirming the findings in GP-IT treatment in allergic rhinitis [179] .
Less is known about the molecular mechanisms behind TGF--mediated suppression in allergen-SIT. In a murine model of allergic inflammation, blocking of CTLA-4 was associated with decreased TGF-levels within the bronchoalveolar lavage fluid [180] . TGF-has been shown to deviate antibody response against allergen from an IgE to an IgA-dominated response in mice and in man post IT [181] .
Based on these data, and given the fact that decreases in T Reg cell populations are possibly one of the major causes of allergic diseases, the upregulation of T Regs numerically or functionally holds promising therapeutic potential in the treatment of allergic diseases. Novel approaches should be adopted to improve the clinical efficacy of IT using adjuvant(s) such as vitamin D3 or CpG or cytokines e.g. IL-10. Treatment of mice with mycobacterium induced allergenspecific T Regs producing IL-10 and TGF-protected against airway inflammation [182] . The application of adenoviral vectors encoding IL-10 also resulted in a longer suppressive effect than injected IL-10, with a very limited half-life [183] . Alternatively immunostimulatory CpG motifs, an agonist of TLR9 [184] has been demonstrated to reduce allergenicity and improve clinical efficacy of treatment when combined with pollen immunotherapy.
CONCLUSIONS

Naturally occurring CD4
+ CD25 + regulatory T cells (T Regs ) play a critical role in the control of periphery tolerance to self-antigens and the prevention of autoimmunity. Evidence from experimental models and studies in man have also demonstrated a key role for T Regs in allergic diseases including rhinitis, atopic dermatitis, and asthma. Significant progress has been made in understanding specific mechanisms resulting in allergic inflammation. Foxp3 expressing CD4 + CD25 + T Regs and IL-10 producing Tr-1 cells capable of suppressing Th2 responses to allergens seem to be defective in those who develop allergic sensitization. The exact mechanism of suppression also remains controversial and may vary for different regulatory populations. Better understanding of regulatory mechanisms involved in the development of allergic sensitization and the manipulation of these cells holds the promise of effective treatment strategies to prevent allergic disease. Allergen immunotherapy modifies T cell responses to allergen and may do so through induction of adaptive T Regs , e.g. IL-10-producing Tr-1 cells contributing to the clinical efficacy of the treatment in aeroallergen sensitive individuals. Adoptive transfer of T Regs may represent an effective, donor-specific therapeutic approach, although it can also be cost effective. In vivo induction or expansion of T Regs in patients remains an attractive option and may present a more realistic approach to improve allergenspecific T Reg induction and provide significant benefits to allergic and asthmatic patients.
Allergen immunotherapy may enhance the development of allergen-specific T Regs and provides safe, specific, and long-term control of allergic diseases and asthma. Coadministration of specific allergen immunotherapy with drugs such as corticosteroids and agents, e.g. vitamin D 3 , adjuvants for example CpG or cytokine IL-10 are strong candidates for enhancing and generating antigen specific regulatory responses. 
